A developer targeting cervical cancer tumor lesions and metastatic lymph nodes, and its preparation method and application
By developing nanoparticle developer, using a complex doped with manganese Prussian blue and near-infrared fluorescent dyes, combined with targeting small molecule glycosides in cervical cancer cells, the problem of difficult to accurately judge cervical cancer lymph node metastasis in the existing technology is solved, and the problem of realizing the High specific MRI and near-infrared imaging improve the diagnosis and treatment accuracy of metastatic lymph nodes of cervical cancer.
Patent Information
- Application Number
- CN202410245240.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-05
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-03-05
AI Technical Summary
It is difficult to accurately determine the lymph node metastasis status of patients with cervical cancer, especially lymph nodes of normal size, which are often ignored, resulting in a low diagnosis rate.
Develop a nanoparticle developer, which is compounded by polyethylene glycol, manganese-doped Prussian blue and near-infrared fluorescent dyes, combined with small molecule glycosides targeting cervical cancer cells, is prepared by microemulsion method and ultrasonic decompression rotary distillation, to enhance MRI and near-infrared imaging effects to achieve targeted imaging.
The developer has high penetration depth, sensitivity, signal-to-noise ratio and biosafety, and can develop cervical cancer metastatic lymph nodes in real time during surgery, improve the accuracy of preoperative staging and the choice of treatment plans, and achieve high cervical cancer metastatic lymph nodes. Specific MRI and near-infrared fluorescence imaging.
Smart Images

Figure HDA0004725659920000011 
Figure HDA0004725659920000012 
Figure HDA0004725659920000021
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of nuclear magnetic resonance and near-infrared dual-modality developer, and in particular relates to a developer targeting cervical cancer tumor lesions and metastatic lymph nodes, and a preparation method and application thereof. Background Art
[0002] Cervical cancer is one of the most common gynecological malignancies in the world. Patients with combined lymph node metastasis have a poor oncological prognosis, which is an independent prognostic factor affecting the treatment of cervical cancer. Accurate judgment of lymph node status before surgery is crucial for the staging and treatment decisions of cervical cancer. Currently, preoperative imaging examinations and intraoperative lymph node biopsies used in clinical practice only use lymph node size and texture as judgment criteria. Previous studies have shown that about 50% to 80% of the metastatic lymph nodes of cervical cancer patients are normal-sized lymph nodes. These lymph nodes are often overlooked, which is also a bottleneck problem encountered in improving the diagnosis rate of metastatic lymph nodes.
[0003] Therefore, there is an urgent need for an imaging method that can specifically determine whether lymph nodes have metastasized before and during surgery. Summary of the invention
[0004] The present invention aims to solve at least one of the technical problems existing in the prior art. To this end, the present invention provides a developer, which has the advantages of high penetration depth, high sensitivity, high signal-to-noise ratio, strong cancer lesion targeting, good biological safety, etc., improves the water solubility and biocompatibility of near-infrared fluorescent dyes, and has excellent imaging quality.
[0005] The first aspect of the present invention aims to provide a bimodal developer.
[0006] The second aspect of the present invention aims to provide a method for preparing the developer of the first aspect of the present invention.
[0007] The third aspect of the present invention aims to provide the use of the developer of the first aspect of the present invention in preparing nuclear magnetic resonance / near infrared reagents or screening cervical cancer therapeutic drugs or evaluating the suitability of treatment plans for cervical cancer patients.
[0008] The fourth aspect of the present invention aims to provide a product.
[0009] In order to achieve the above object, the technical solution adopted by the present invention is:
[0010] The first aspect of the present invention provides a developer, which is formed by coupling nanoparticles and small molecule glycosides targeting cervical cancer cells.
[0011] In some embodiments of the present invention, the nanoparticles are composited by polyethylene glycol, a manganese-doped MRI imaging agent and a near-infrared fluorescent dye.
[0012] In some embodiments of the invention, the MRI imaging agent comprises Prussian blue.
[0013] Prussian blue Pb to Mn 2+ Doping greatly enhances the effect of magnetic resonance imaging.
[0014] In some embodiments of the present invention, the near-infrared fluorescent dye is a carboxyl-terminated near-infrared fluorescent dye.
[0015] In some embodiments of the present invention, the near-infrared fluorescent dye includes at least one of cyanines, fluoroboranes, rhodamines, squaric acids, and porphyrins.
[0016] In some embodiments of the present invention, the near-infrared fluorescent dye is IR820.
[0017] IR820 targets and accumulates in metastatic cervical cancer lymph nodes, emitting red fluorescence under near-infrared imaging.
[0018] In some embodiments of the present invention, the polyethylene glycol is hydroxylated polyethylene glycol (DSPE-PEG-COOH).
[0019] In some embodiments of the present invention, the molecular weight of the polyethylene glycol is 0.5 kD to 2 kD.
[0020] In some embodiments of the present invention, the molecular weight of the polyethylene glycol is 1 kD to 1.5 kD.
[0021] In some embodiments of the present invention, the nanoparticles are polyethylene glycol-coated Mn2 + Doped Prussian blue and near-infrared fluorescent dyes.
[0022] In some embodiments of the present invention, the method for preparing the nanoparticles comprises the following steps:
[0023] S1: Preparation of manganese-doped MRI imaging agents by microemulsion method;
[0024] S2: mixing the manganese-doped MRI imaging agent with near-infrared fluorescent dye and polyethylene glycol, and subjecting the mixture to ultrasound for 10 to 20 minutes.
[0025] Vacuum evaporation at 40-50°C for 10-20 min to obtain nanoparticles;
[0026] In some embodiments of the present invention, the specific process of step S1 is as follows:
[0027] The oil phase and K3[Fe(CN)6] were mixed to obtain microemulsion 1;
[0028] The oil phase is mixed with MnCl2 and FeCl2 to obtain microemulsion 2;
[0029] The microemulsion 2 is slowly added dropwise to the microemulsion 1 under magnetic stirring, reacted at 20-30°C for 1-4h, demulsified in a water bath at 95-100°C for 10-30min, the oil phase is removed by aspiration, the supernatant is discarded by centrifugation, and the manganese-doped MRI imaging agent is obtained.
[0030] In some embodiments of the present invention, the oil phase is obtained by uniformly mixing Triton X-100, n-hexanol and cyclohexane in a mass ratio of 2 to 3:1:1.
[0031] In some embodiments of the present invention, the mass ratio of the oil phase to K3[Fe(CN)6](0.05mol / L) is 2 to 3:1.
[0032] In some embodiments of the present invention, the mass ratio of MnCl2 (0.05 mol / L), FeCl2 (0.05 mol / L) and oil phase is 1:3-5:12-14.
[0033] In some embodiments of the present invention, the mass ratio of the manganese-doped MRI imaging agent, the near-infrared fluorescent dye, and polyethylene glycol is 4:4:5.
[0034] In some embodiments of the present invention, the small molecule glycoside targeting cervical cancer cells is thiodilactoside.
[0035] In some embodiments of the present invention, the developer is a pelvic developer. The developer can visualize cervical cancer metastatic lymph nodes in real time during surgery, and has both cervical cancer metastatic lymph node MRI imaging and near-infrared fluorescence imaging effects, and shows great prospects in the application of accurate preoperative staging to guide the selection of treatment plans and real-time navigation for accurate resection of metastatic lymph nodes during surgery.
[0036] In some embodiments of the present invention, the particle size of the developer is 100-120 nm.
[0037] In some embodiments of the present invention, the particle size of the imaging agent is 110-120 nm, thereby prolonging the imaging agent's circulation time in the body and retention in the lymph nodes.
[0038] The second aspect of the present invention provides a method for preparing the developer of the first aspect of the present invention, comprising the following steps: mixing a small molecule glycoside targeting cervical cancer cells with nanoparticles, and performing a coupling reaction to obtain the developer.
[0039] In some embodiments of the present invention, the mixing condition is magnetic stirring for 1 to 3 hours.
[0040] In some embodiments of the present invention, the mixing condition is magnetic stirring for 1 to 2 hours.
[0041] In some embodiments of the present invention, the mixing condition is magnetic stirring for 2 hours.
[0042] In some embodiments of the present invention, the coupling reaction comprises adding a coupling agent into the system and reacting for 10 to 16 hours under stirring conditions.
[0043] In some embodiments of the present invention, the coupling reaction comprises adding a coupling agent into the system and reacting for 10 to 14 hours under stirring conditions.
[0044] In some embodiments of the present invention, the coupling reaction comprises adding a coupling agent into the system and reacting for 12 hours under stirring conditions.
[0045] In some embodiments of the present invention, the coupling agent includes (3-dimethylaminopropyl)-3-ethylcarbodiimide and sulfo N-hydroxysuccinimide.
[0046] In some embodiments of the present invention, the mass ratio of the nanoparticles to the small molecule glycoside targeting cervical cancer cells is 3 to 10:1.
[0047] In some embodiments of the present invention, the mass ratio of the nanoparticles to the small molecule glycoside targeting cervical cancer cells is 3 to 5:1.
[0048] In some embodiments of the present invention, the reaction needs to be carried out under light-proof conditions.
[0049] In some embodiments of the present invention, the mass ratio of the small molecule glycoside targeting cervical cancer cells to EDC and NHS is 1:1-3:1-3.
[0050] In some embodiments of the present invention, the mass ratio of the cervical cancer cell targeting small molecule glycoside to EDC and NHS is 1:2:2.
[0051] Prussian Blue (PB) has been approved by the FDA for the treatment of acute and chronic cesium and thallium metal poisoning. It has excellent biosafety. PB-based molecular probes have become one of the most promising multimodal probes for clinical transformation. The Prussian Blue-based nanoparticles prepared by the present invention are used for multimodal imaging of cervical cancer tumor tissue and metastatic lymph nodes. Mn is doped during the synthesis process. 2+ , making it have excellent MRI imaging capabilities, loading IR820 makes it have near-infrared fluorescence imaging capabilities, and coupling with TDG makes it have the ability to target cervical cancer cells. At the same time, this method is simple and does not require high professional skills from the operator.
[0052] The third aspect of the present invention provides the use of the developer in preparing nuclear magnetic resonance / near infrared reagents or screening cervical cancer therapeutic drugs or evaluating the applicability of cervical cancer treatment plans.
[0053] In some embodiments of the invention, the reagent comprises a diagnostic tracer.
[0054] A fourth aspect of the present invention provides a product comprising the developer according to the first aspect of the present invention.
[0055] In some embodiments of the present invention, the product has the following functions: screening drugs for treating cervical cancer, evaluating the suitability of treatment plans for cervical cancer, and diagnosing cervical cancer.
[0056] The beneficial effects of the present invention are:
[0057] The developer provided by the present invention has the advantages of high penetration depth, high sensitivity, high signal-to-noise ratio, strong cancer lesion targeting, good biosafety, etc. It improves the water solubility and biocompatibility of near-infrared fluorescent dyes, and has excellent imaging quality. It can be used as a multimodal developer to achieve fluorescence / MRI imaging of cervical cancer metastatic lymph nodes before and during surgery, and can achieve high-specificity MRI imaging of cervical cancer metastatic lymph nodes before surgery and real-time near-infrared fluorescence imaging during surgery to guide the accurate evaluation and removal of cervical cancer metastatic lymph nodes. Compared with existing near-infrared fluorescence imaging developers and magnetic resonance imaging agents, the developer provided by the present invention has stronger cancer tissue specificity and positioning ability. BRIEF DESCRIPTION OF THE DRAWINGS
[0058] Figure 1 This is a transmission electron microscopy image of TDG@PEG@MnPb-IR820 provided in an embodiment of the present invention.
[0059] Figure 2 Elemental analysis results of TDG@PEG@MnPb-IR820 provided in the embodiments of the present invention.
[0060] Figure 3 This is the UV-visible absorption spectrum of TDG@PEG@MnPb-IR820 provided in the embodiments of the present invention.
[0061] Figure 4 Infrared spectra of TDG@PEG@MnPb-IR820 and PEG@MnPb-IR820 provided in the embodiments of the present invention.
[0062] Figure 5 A graph showing the relationship between the concentration and relaxation rate of TDG@PEG@MnPb-IR820 provided in an embodiment of the present invention.
[0063] Figure 6 This is a statistical result diagram of the relationship between the concentration and relaxation rate of TDG@PEG@MnPb-IR820 provided in an embodiment of the present invention.
[0064] Figure 7This is a near-infrared molecular image of the paw pad of SD rats injected with TDG@PEG@MnPb-IR820 provided in an embodiment of the present invention.
[0065] Figure 8 MRI images of SD rats after injection of TDG@PEG@MnPb-IR820 provided in an embodiment of the present invention.
[0066] Fig. 9 The Siha cell uptake test results of TDG@PEG@MnPb-IR820 provided in the embodiments of the present invention. DETAILED DESCRIPTION
[0067] The present invention is further described in detail below through specific examples.
[0068] It should be understood that these embodiments are only used to illustrate the present invention and are not used to limit the scope of the present invention.
[0069] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0070] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.
[0071] Unless otherwise specified, the room temperature in the following examples refers to 25±5°C.
[0072] The Balb / c nude mice used in the following examples were provided by the Animal Center of Southern Medical University; the molecular weight of DSPE-PEG-COOH was 2000.
[0073] Example 1
[0074] A method for preparing a cervical cancer metastatic lymph node fluorescence / MRI (magnetic resonance imaging) multimodal imaging agent (TDG@PEG@MnPb-IR820), specifically comprising the following steps:
[0075] 1) Preparation of manganese-doped Prussian blue nanoparticles MnPb by microemulsion method
[0076] Triton X-100, n-hexanol and cyclohexane were mixed in a mass ratio of 2:1:1 to obtain oil phase EAX. 20 mL of 0.05 mol / L MnCl2, FeCl2 and potassium ferrocyanide solution were prepared respectively, and 800 mg of citric acid was added respectively and ultrasonicated until clear and transparent. 8 g of EAX and 3 g of K3[Fe(CN)6] aqueous solution (0.05 mol / L) were mixed to obtain microemulsion 1. 8 g of EAX, 0.6 g of MnCl2 aqueous solution (0.05 mol / L) and 2.4 g of FeCl2 aqueous solution (0.05 mol / L) were mixed to obtain microemulsion 2. Microemulsion 2 was slowly added dropwise to microemulsion 1 under magnetic stirring and reacted at room temperature for 2 h. After the reaction is completed, the mixture is placed in a 100°C water bath for 15 minutes to break the emulsion, the oil phase is removed by suction, the supernatant is discarded after centrifugation at 7000 rpm for 5 minutes, and then washed three times with 5 mL of water + 15 mL of tetrahydrofuran, 5 mL of water + 25 mL of tetrahydrofuran, and 20 mL of tetrahydrofuran. Finally, 10 mL of anhydrous ethanol is used to make the volume to obtain the MnPb mother liquor, that is, the manganese-doped Prussian blue nanoparticles MnPb are obtained.
[0077] 2) Synthesis of PEG@MnPb-IR820 by thin film hydration method
[0078] Take 500uL of MnPb mother solution and dilute it to 5ml, add 18mg DSPE-PEG-COOH and 10mg IR820, ultrasonicate for 10min, put it into a round-bottom flask in a water bath at 40-45℃ and evaporate it under reduced pressure for 10min until a uniform lipid film is formed on the bottom of the flask, add 5mL of deionized water, shake the flask to hydrate and fall off the lipid film to produce liposome dispersion PEG@MnPb-IR820, and ultrasonicate for 3min to obtain PEG@MnPb-IR820.
[0079] 3) TDG coupled with PEG@MnPb-IR820
[0080] Thiodilactoside (1 mg) was dissolved in water, ultrasonicated for 1 min, and then the above liposome dispersion PEG@MnPb-IR820 was added. The mixture was stirred magnetically for 2 h at room temperature to mix evenly. 2 mg (3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) and 2 mg sulfo-N-hydroxysuccinimide (NHS) were added, and magnetic stirring was continued overnight (10-14 h). Finally, the stock solution of TDG@PEG@MnPb-IR820 was obtained by dialysis for 24 h, and then freeze-dried for use.
[0081] Comparative Example 1
[0082] The only difference between this comparative example and Example 1 is that step 3) is omitted, and PEG@MnPb-IR820 is prepared.
[0083] Effect Example
[0084] 1. Transmission electron microscopy characterization of TDG@PEG@MnPb-IR820
[0085] The particle size of TDG@PEG@MnPb-IR820 was characterized by high-resolution transmission electron microscopy (JEM-2100, JEOL Ltd., Japan).
[0086] The results show that the particle size of TDG@PEG@MnPb-IR820 prepared in Example 1 is 100-120 nm, and there is no large aggregation phenomenon ( Figure 1 ), elemental analysis shows that Fe and Mn are successfully doped ( Figure 2 ).
[0087] 2. Detection of UV characteristic absorption peak of TDG@PEG@MnPb-IR820
[0088] The spectral scanning of TDG@PEG@MnPb-IR820 aqueous solution was performed using a fluorescence spectrophotometer (ND-1000, NanoDrop, USA) in the wavelength range of 200 nm to 1000 nm.
[0089] The results are as follows Figure 3 As shown, TDG@PEG@MnPb-IR820 has characteristic peaks of Mn and IR820 at 740nm and 820nm.
[0090] 3. Detection of infrared characteristic absorption peaks of TDG@PEG@MnPb-IR820 and PEG@MnPb-IR820
[0091] The powder obtained after drying was taken, and the infrared spectra of TDG@PEG@MnPb-IR820 and PEG@MnPb-IR820 were detected by a Thermo Fisher Nicolet iS50 FT-IR Fourier transform infrared spectrometer.
[0092] The results are as follows Figure 4 As shown, it can be seen that TDG@PEG@MnPb-IR820 has a TDG characteristic peak compared with PEG@MnPb-IR820, indicating that TDG is successfully coupled to PEG@MnPb-IR820.
[0093] 4. MRI Relaxation Rate Analysis of TDG@PEG@MnPb-IR820
[0094] A 3.0T MRI scanner (Achieva, Philips, The Netherlands, equipped with an 8-channel head coil) was used to measure the T1 relaxation times of aqueous solutions of TDG@PEG@MnPb-IR820 with concentrations of 0, 0.625, 1.25, 2.5, 5.0, and 10.0 mg / mL.
[0095] The results are as follows Figure 5 As shown in the figure, with the increase of concentration, the T1 signal increases linearly; the r1 value of TDG@PEG@MnPb-IR820 is calculated to be 5.372 (mmol / L) -1 s -1 , indicating potential for MRI imaging.
[0096] 5. Multimodal Imaging of Metastatic Lymph Nodes in Pelvic Cervical Cancer in Animal Models
[0097] Animal model: Cervical cancer Siha cells (about 3 million / mouse) were injected into the paw pads of 4-6 week-old Balb / c nude mice. Tumors formed after 2 weeks and major lymph nodes could be felt in the popliteal fossa.
[0098] Nude mice were anesthetized with 0.2 mL of 1% sodium pentobarbital on a clean bench, and PEG@MnPb-IR820 and TDG@PEG@MnPb-IR820 with the same PEG@MnPb-IR820 concentration (2 mg / mL) were injected through the paw pad, and the same volume of PBS was injected as a control group. Fluorescence imaging of paw pad tumors and metastatic lymph nodes was taken using a near-infrared molecular imaging intraoperative navigation system (DPM-1, Beijing Digital Precision Medical Technology, China) at 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 14 hours, 18 hours, and 24 hours after injection.
[0099] The results showed that as time went on, the fluorescence signals in the nude mouse paw pad area and popliteal lymph node metastasis area gradually increased. Six hours after injection, the popliteal lymph nodes showed strong clustering, which lasted for 4 hours. Figure 6 ). It is proved that nanomaterials can be targeted and accumulated in metastatic lymph nodes through the lymphatic vessels in the tumor drainage area and have a longer effective development time.
[0100] Twelve hours after the paw pad was injected with TDG@PEG@MnPb-IR820 and PEG@MnPb-IR820, the paw pad tumor, popliteal metastatic lymph node, contralateral popliteal lymph node, heart, liver, spleen, lung, and kidney were dissected and imaged with NIR fluorescence using an in vitro small animal imaging device. The results are shown in Figure 2. Figure 7As shown (LNl: left metastatic popliteal lymph node, LNr: right normal popliteal lymph node, Tu: left paw pad in situ tumor, He: heart, Li: liver, Sp: spleen, Lu: lung, Ki: kidney, Br: brain). The nanoprobe was mainly cleared through the liver and kidney pathways. After 12 hours of paw pad injection, the in situ paw pad tumor still had strong fluorescence imaging, and TDG@PEG@MnPb-IR820 still had targeted enrichment of popliteal metastatic lymph nodes.
[0101] According to the results of near-infrared fluorescence imaging, a 3.0T MRI scanner (Achieva, Philips, The Netherlands) was used to perform 3.0T magnetic resonance T1 coronal scans of small animals before drug administration and at the time point when the fluorescence intensity of the lymph nodes was the highest to obtain MRI images, such as Figure 8 The T1-weighted images of the popliteal lymph node metastasis after injection of the material showed uneven signal enhancement. The image analysis software (RadiAnt DICOM Viewer 34.1) was used to calculate the signal-to-noise ratio increment. The Δ signal-to-noise ratio (T1) of the popliteal lymph node metastasis was 13.69-8.16=5.53.
[0102] 6. Cell experiments
[0103] The prepared PEG@MnPb-IR820 and TDG@PEG@MnPb-IR820 solutions were diluted with DMEM culture medium so that the PEG@MnPb-IR820 content was 0.25 mg / mL.
[0104] Cell treatment: Siha cells (2×10 5 / well) were inoculated in the confocal dish and cultured for 24 hours. The culture medium in the well plate was replaced with the culture medium of PEG@MnPb-IR820 or TDG@PEG@MnPb-IR820 at 1 hour, 6 hours, and 12 hours, respectively. After incubation for the corresponding time, the cells were washed 2 to 3 times with PBS.
[0105] Cell fluorescence imaging observation: The cells were fixed with 4% paraformaldehyde at room temperature for 20-30 min. The cells were placed under a confocal laser scanning microscope (CLSM, Olympus FV500, Japan) to obtain confocal fluorescence images of cell uptake at each time point, and the fluorescence intensity was analyzed using ImageJ.
[0106] The results are as follows Fig. 9 As shown in the figure, with the extension of time, the fluorescence intensity of the cells gradually increased, showing all the red fluorescence of IR820. At 6 hours, the uptake of TDG@PEG@MnPb-IR820 by Siha cells was close to saturation, and was significantly higher than that of PEG@MnPb-IR820 (P < 0.0001).
[0107] The embodiments of the present invention are described in detail above in conjunction with the accompanying drawings, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.
Claims
1. A developer, which is made of nanoparticles coupled with small molecule glycosides targeting cervical cancer cells; The small molecule glycoside targeting cervical cancer cells is thiodilactoside; The nanoparticles are composited with polyethylene glycol, a manganese-doped MRI imaging agent and a near-infrared fluorescent dye; The MRI imaging agent is Prussian blue, the near-infrared fluorescent dye is IR820, and the polyethylene glycol is carboxylated polyethylene glycol.
2. The method for preparing the developer according to claim 1, The following steps are involved: The developer is obtained by mixing small molecule glycoside targeting cervical cancer cells with nanoparticles and performing coupling reaction.
3. The preparation method according to claim 2, wherein the mixing condition is magnetic stirring for 1 to 3 hours; and / or the coupling reaction comprises adding a coupling agent to the system and reacting under stirring conditions for 10 to 16 hours.
4. The preparation method according to claim 3, It is characterized in that The coupling agents include (3-dimethylaminopropyl)-3-ethylcarbodiimide and sulfo-N-hydroxysuccinimide.
5. Use of the developer according to claim 1 in preparing nuclear magnetic resonance / near infrared reagents or screening drugs for treating cervical cancer.
6. A product comprising the developer according to claim 1.
